newsfilter
← Latest News
GlobeNewswire·

Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026

World's first Phase 3 readout for an in vivo CRISPR gene editing candidateCompany to host webcast to discuss data at 8:00 a.m. ET on April 27, 2026 CAMBRIDGE, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Intellia